Delays in Contract Projects for High-Potency Injectable Manufacturing Equipment and a ¥4,093 Million Impairment Loss
First written in FY2024. 2 of 2 entries say "Materialised", first in FY2024. Latest entry: FY2025-H1.
Astena Holdings moved to the "Worse" side of this theme in 2025, 1 year after the typical company in this theme (2024).
The whole theme swung hardest in 2026: 19 of 24 companies on the "Worse" side.
26 other companies' latest entry also says "Materialised".
- FY2025-H1MaterialisedAnnual report
「In light of the business environment surrounding the high-potency injectable business at the Iwaki Pharmaceutical Sakura Plant, and in view of the increasing uncertainty regarding the outlook for order timing, which is the basis for the business's sales plan, the Group determined that it would be difficult to recover the investment within the eight-year economic useful life of the major assets. Accordingly, ¥118 million was recorded as an impairment loss under extraordinary losses.」
As uncertainty increased regarding the outlook for order timing in the high-potency injectable business, an additional impairment loss of ¥118 million was recognized on construction in progress. - FY2024MaterialisedAnnual report
「The start of operations at the high-potency injectable manufacturing equipment was delayed from the original plan. … The carrying amounts of these assets were reduced to their recoverable value, and the resulting reduction of ¥4,093,056 thousand was recognised as an impairment loss.」
Time was required to coordinate and negotiate terms with customers in the high-potency injectable business, substantially delaying the order timing for major contract manufacturing projects. As a result, the recoverable amount of the facilities was determined to be zero, and an impairment loss of ¥4,093.056 million was recognized.